$2.78 Billion is the total value of DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s 97 reported holdings in Q2 2019. The portfolio turnover from Q1 2019 to Q2 2019 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| HZNP | New | HORIZON THERAPEUTICS PUB LTD | $155,491,000 | – | 6,462,634 | +100.0% | 5.58% | – |
| New | INSULET CORPnote 1.375%11/1 | $52,097,000 | – | 36,650,000 | +100.0% | 1.87% | – | |
| MNKKQ | New | MALLINCKRODT PUB LTD CO | $38,356,000 | – | 4,178,219 | +100.0% | 1.38% | – |
| CHRS | New | COHERUS BIOSCIENCES INC | $37,084,000 | – | 1,678,022 | +100.0% | 1.33% | – |
| New | PTC THERAPEUTICS INCnote 3.000% 8/1 | $27,557,000 | – | 24,877,000 | +100.0% | 0.99% | – | |
| STAA | New | STAAR SURGICAL CO | $25,752,000 | – | 876,512 | +100.0% | 0.92% | – |
| SILK | New | SILK ROAD MEDICAL INC | $24,183,000 | – | 499,030 | +100.0% | 0.87% | – |
| HUM | New | HUMANA INC | $17,775,000 | – | 67,000 | +100.0% | 0.64% | – |
| GBT | New | GLOBAL BLOOD THERAPEUTICS IN | $12,361,000 | – | 235,000 | +100.0% | 0.44% | – |
| TPTX | New | TURNING POINT THERAPEUTICS I | $11,703,000 | – | 287,545 | +100.0% | 0.42% | – |
| PHAS | New | PHASEBIO PHARMACEUTICALS INC | $11,165,000 | – | 851,005 | +100.0% | 0.40% | – |
| CHWY | New | CHEWY INCcl a | $9,147,000 | – | 261,337 | +100.0% | 0.33% | – |
| XFOR | New | X4 PHARMACEUTICALS INC | $8,475,000 | – | 565,000 | +100.0% | 0.30% | – |
| BBIO | New | BRIDGEBIO PHARMA INC | $7,821,000 | – | 290,000 | +100.0% | 0.28% | – |
| SRNE | New | SORRENTO THERAPEUTICS INC | $5,584,000 | – | 2,091,461 | +100.0% | 0.20% | – |
| IDYA | New | IDEAYA BIOSCIENCES INC | $4,233,000 | – | 425,000 | +100.0% | 0.15% | – |
| BDSI | New | BIODELIVERY SCIENCES INTL IN | $3,795,000 | – | 816,096 | +100.0% | 0.14% | – |
| MDCO | New | MEDICINES COput | $3,647,000 | – | 100,000 | +100.0% | 0.13% | – |
| ADPT | New | ADAPTIVE BIOTECHNOLOGIES COR | $3,381,000 | – | 70,000 | +100.0% | 0.12% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-08-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AERIE PHARMACEUTICALS INC | 36 | Q3 2022 | 3.6% |
| CENTENE CORP DEL | 30 | Q3 2023 | 3.0% |
| BIOCRYST PHARMACEUTICALS INC | 29 | Q3 2023 | 2.2% |
| MOLINA HEALTHCARE INC | 26 | Q3 2022 | 1.7% |
| EHEALTH INC | 25 | Q3 2020 | 2.0% |
| INTERCEPT PHARMACEUTICALS IN | 24 | Q1 2023 | 2.2% |
| MYLAN NV | 23 | Q3 2020 | 6.2% |
| PORTOLA PHARMACEUTICALS INC | 23 | Q1 2019 | 6.0% |
| BROOKDALE SR LIVING INC | 23 | Q3 2023 | 2.2% |
| ALIMERA SCIENCES INC | 23 | Q3 2019 | 0.8% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| DA32 Life Science Tech Acquisition Corp. | August 01, 2023 | 5,145,000 | 91.1% |
| CareMax, Inc. | March 13, 2023 | 18,691,423 | 16.4% |
| CareMax, Inc. | June 02, 2022 | 18,691,423 | 20.7% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 3 | 2024-03-19 |
| 4 | 2024-03-19 |
| 4 | 2024-03-12 |
| 3 | 2024-03-08 |
| 4 | 2024-02-16 |
| 13F-HR | 2024-02-14 |
| 4 | 2024-02-08 |
| 3 | 2024-02-01 |
| 4 | 2023-11-21 |
| 13F-HR | 2023-11-14 |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.